CONy 2024 | AssistMS: testing the value of an AI tool for MRI scan interpretation in clinical practice

Klaus Schmierer, MB BS, PhD, FRCP, The Blizard Institute, Queen Mary University of London & The Royal London Hospital of Barts Health NHS Trust, London, UK, and Dominic Shadbolt, BA, MSc, Founder of the MSGuide & patient advocate, discuss the launch of the AssistMS project, which will assess the ability of an artificial intelligence tool to enhance the accuracy and efficacy of MRI scan interpretation in patients with multiple sclerosis (MS). MRI follow-up is crucial for tracking progression in MS and investigating the efficacy of disease-modifying therapies, but detecting small changes can be challenging as pathology becomes increasingly complex. icobrain MS software is able to and detect subtle changes in brain MRI, objectively assessing brain volume change metrics and lesion dissemination in space and time. AssistMS will randomize 1300 patients to have their scans assessed by radioloigsts with versus without the support of icobrain MS. The study will investigate the difference in disease activity detected and the clinical decisions made as a result. It is hoped that the three-year project will demonstrate the potential of AI support tools to improve patient outcomes through improved detection of subtle brain changes and consequently, better-informed treatment decisions. Prof. Scheimer and Mr Shadbolt discuss what this approach would mean for patients. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.